Medical therapy approach for treating abdominal aortic aneurysm

Mark E. Rentschler, Bernard Timothy Baxter

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Abdominal aortic aneurysm (AAA) is a common and deadly problem. The aortic diameter increases in association with a complex remodeling process that includes changes in the structure and content of key proteins, elastin and collagen. As these changes occur, the tissue mechanical properties also change. The natural history of AAA is progressive enlargement to a point of mechanical tissue failure, typically followed by death. Currently, the marker used to predict the risk of impending rupture is the largest transverse diameter. After reaching a diameter threshold of 5.5 cm, the aneurysm is surgically repaired. This criterion does not consider any patient-specific information or the known heterogeneity of the aneurysm that may, in some cases, lead to rupture before the aneurysm reaches the standard intervention threshold. Conversely, in many patients, continued observation beyond this threshold is safe. Although no medical treatment is yet approved, doxycycline has been shown to greatly reduce aortic aneurysm growth in animal models and has been shown to slow growth in several small clinical trials. Although larger prospective randomized trials are needed, one unknown is what effect doxycycline has on the structural integrity of the aortic wall. That is, does slowed aneurysm growth by doxycycline treatments, in fact, prevent rupture, or does the wall continue to weaken and the aneurysm instead ruptures at a smaller diameter? Research has begun to answer these questions before a large clinical trial begins.

Original languageEnglish (US)
Pages (from-to)361-365
Number of pages5
JournalVascular
Volume15
Issue number6
DOIs
StatePublished - Nov 1 2007

Fingerprint

Abdominal Aortic Aneurysm
Aneurysm
Doxycycline
Rupture
Growth
Clinical Trials
Therapeutics
Elastin
Aortic Aneurysm
Collagen
Animal Models
Observation
Research
Proteins

Keywords

  • Aortic aneurysm
  • Doxycycline
  • Mechanical properties
  • Medical treatment

ASJC Scopus subject areas

  • Surgery
  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Medical therapy approach for treating abdominal aortic aneurysm. / Rentschler, Mark E.; Baxter, Bernard Timothy.

In: Vascular, Vol. 15, No. 6, 01.11.2007, p. 361-365.

Research output: Contribution to journalReview article

Rentschler, Mark E. ; Baxter, Bernard Timothy. / Medical therapy approach for treating abdominal aortic aneurysm. In: Vascular. 2007 ; Vol. 15, No. 6. pp. 361-365.
@article{9f4e57ac4592406cbb2a1cbd3915bc9c,
title = "Medical therapy approach for treating abdominal aortic aneurysm",
abstract = "Abdominal aortic aneurysm (AAA) is a common and deadly problem. The aortic diameter increases in association with a complex remodeling process that includes changes in the structure and content of key proteins, elastin and collagen. As these changes occur, the tissue mechanical properties also change. The natural history of AAA is progressive enlargement to a point of mechanical tissue failure, typically followed by death. Currently, the marker used to predict the risk of impending rupture is the largest transverse diameter. After reaching a diameter threshold of 5.5 cm, the aneurysm is surgically repaired. This criterion does not consider any patient-specific information or the known heterogeneity of the aneurysm that may, in some cases, lead to rupture before the aneurysm reaches the standard intervention threshold. Conversely, in many patients, continued observation beyond this threshold is safe. Although no medical treatment is yet approved, doxycycline has been shown to greatly reduce aortic aneurysm growth in animal models and has been shown to slow growth in several small clinical trials. Although larger prospective randomized trials are needed, one unknown is what effect doxycycline has on the structural integrity of the aortic wall. That is, does slowed aneurysm growth by doxycycline treatments, in fact, prevent rupture, or does the wall continue to weaken and the aneurysm instead ruptures at a smaller diameter? Research has begun to answer these questions before a large clinical trial begins.",
keywords = "Aortic aneurysm, Doxycycline, Mechanical properties, Medical treatment",
author = "Rentschler, {Mark E.} and Baxter, {Bernard Timothy}",
year = "2007",
month = "11",
day = "1",
doi = "10.2310/6670.2007.00055",
language = "English (US)",
volume = "15",
pages = "361--365",
journal = "Vascular",
issn = "1708-5381",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Medical therapy approach for treating abdominal aortic aneurysm

AU - Rentschler, Mark E.

AU - Baxter, Bernard Timothy

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Abdominal aortic aneurysm (AAA) is a common and deadly problem. The aortic diameter increases in association with a complex remodeling process that includes changes in the structure and content of key proteins, elastin and collagen. As these changes occur, the tissue mechanical properties also change. The natural history of AAA is progressive enlargement to a point of mechanical tissue failure, typically followed by death. Currently, the marker used to predict the risk of impending rupture is the largest transverse diameter. After reaching a diameter threshold of 5.5 cm, the aneurysm is surgically repaired. This criterion does not consider any patient-specific information or the known heterogeneity of the aneurysm that may, in some cases, lead to rupture before the aneurysm reaches the standard intervention threshold. Conversely, in many patients, continued observation beyond this threshold is safe. Although no medical treatment is yet approved, doxycycline has been shown to greatly reduce aortic aneurysm growth in animal models and has been shown to slow growth in several small clinical trials. Although larger prospective randomized trials are needed, one unknown is what effect doxycycline has on the structural integrity of the aortic wall. That is, does slowed aneurysm growth by doxycycline treatments, in fact, prevent rupture, or does the wall continue to weaken and the aneurysm instead ruptures at a smaller diameter? Research has begun to answer these questions before a large clinical trial begins.

AB - Abdominal aortic aneurysm (AAA) is a common and deadly problem. The aortic diameter increases in association with a complex remodeling process that includes changes in the structure and content of key proteins, elastin and collagen. As these changes occur, the tissue mechanical properties also change. The natural history of AAA is progressive enlargement to a point of mechanical tissue failure, typically followed by death. Currently, the marker used to predict the risk of impending rupture is the largest transverse diameter. After reaching a diameter threshold of 5.5 cm, the aneurysm is surgically repaired. This criterion does not consider any patient-specific information or the known heterogeneity of the aneurysm that may, in some cases, lead to rupture before the aneurysm reaches the standard intervention threshold. Conversely, in many patients, continued observation beyond this threshold is safe. Although no medical treatment is yet approved, doxycycline has been shown to greatly reduce aortic aneurysm growth in animal models and has been shown to slow growth in several small clinical trials. Although larger prospective randomized trials are needed, one unknown is what effect doxycycline has on the structural integrity of the aortic wall. That is, does slowed aneurysm growth by doxycycline treatments, in fact, prevent rupture, or does the wall continue to weaken and the aneurysm instead ruptures at a smaller diameter? Research has begun to answer these questions before a large clinical trial begins.

KW - Aortic aneurysm

KW - Doxycycline

KW - Mechanical properties

KW - Medical treatment

UR - http://www.scopus.com/inward/record.url?scp=37349066468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349066468&partnerID=8YFLogxK

U2 - 10.2310/6670.2007.00055

DO - 10.2310/6670.2007.00055

M3 - Review article

C2 - 18053421

AN - SCOPUS:37349066468

VL - 15

SP - 361

EP - 365

JO - Vascular

JF - Vascular

SN - 1708-5381

IS - 6

ER -